Lussoma®

For Clinician Use Only

Overview of Composition, Biochemical Mechanisms, and Professional Handling

Lussoma is a buffered, stabilized iodine complex designed to restore immune resilience through redox modulation and endogenous antimicrobial activation.

Lussoma invites you to step into the realm of a new tier of precision, where redox-targeted chemistry interfaces with immune signaling, epithelial integrity, and oxidative control in chronically stressed systems.



Restoring the Endogenous Defense System

When the body is under chronic stress, whether from lingering infections, viral overload, or systemic inflammation, its innate defenses begin to break down. One of the most important systems affected is the lactoperoxidase system, a redox-based enzyme pathway that produces hypoiodous acid (HOI), a powerful antimicrobial compound.

This system relies on three key components: lactoperoxidase enzyme, hydrogen peroxide (H_2O_2), and iodide. In a healthy body, these components work together to generate HOI in a controlled, physiologic way. But in chronic illness, this system becomes compromised, not necessarily because the enzyme is missing, but because the environment in which it needs to function is disrupted. When the body's redox terrain is unstable, little or no HOI is produced, enabling stealth pathogens to persist.

The root issue? Redox imbalance.

Molecular Stability—Solved


Iodine and iodide are among the most potent modulators of redox balance, immune signaling, and mucosal defense known to molecular biology; however, their therapeutic potential remains largely untapped, not because they lack efficacy, but because they are too effective, too reactive, and too harsh in conventional forms. High-dose iodine is notoriously difficult for the body to handle, often triggering oxidative stress or mucosal irritation when administered without buffering or control.



Lussoma was created to solve this problem. Its proprietary, trade-secret matrix is composed of multiple GRAS-classified compounds that work in synchrony to buffer, stabilize, and escort iodine/iodide into the system in a way that is highly bioavailable without the collateral damage. This enables therapeutically meaningful iodine delivery, whether ingested or used through other physician-directed applications. Until now, no delivery system has achieved this balance. Lussoma makes it possible.

Chronic illness traps the body in a vicious cycle; redox imbalance shuts down the lactoperoxidase system, HOI production collapses, and pathogens drive deeper dysfunction. Lussoma is uniquely designed to break this cycle, restoring redox order and delivering stabilized iodide in a form the body can finally use to restart its own antimicrobial defense.

Redox Imbalance



Redox imbalance shows up in nearly every form of chronic physiologic distress, when the body's equilibrium between pro-oxidant and antioxidant forces is disrupted, typically due to excessive production of reactive oxygen or nitrogen species (ROS/RNS) or diminished antioxidant capacity.

This imbalance results from environmental toxins, heavy metals, radiation, and xenobiotics; nutrient deficiencies (e.g., iodine, selenium, zinc, cysteine) that impair glutathione synthesis; chronic infections and oxidative stress; insulin resistance; and psychological stress or circadian disruption. When sustained, redox imbalance weakens the immune system and creates a terrain favorable to persistent pathogens and chronic inflammation.

Lussoma and Redox Restoration

Lussoma helps restore redox balance by directly supporting the regeneration of thiol-based systems like glutathione and modulating redox-sensitive signaling pathways, including Nrf2 and NF-kB, shifting the immune tone away from chronic inflammation and toward resolution. Its buffered profile allows Lussoma to interface with mucosal surfaces without provoking oxidative irritation, enabling clean and immediate uptake of iodide for the redox and enzymatic processes that depend on it.

Redox Control of Nrf2 and NF-kB

When NF-κB stays chronically activated and Nrf2 becomes insufficient, the body shifts into a persistently inflamed, oxidized state with inadequate antioxidant regeneration. Mitochondria lose redox stability, leading to reduced ATP production, fatigue, and impaired tissue repair. The immune system becomes reactive but ineffective, creating a terrain where chronic illness, biofilms, and persistent pathogen load can easily persist. Lussoma's stabilized electron-donor matrix uniquely replenishes the reduced species that these regulatory systems depend on, interrupting NF-κB–driven oxidative signaling while simultaneously enabling Nrf2-mediated antioxidant gene expression to re-establish control. As oxidative stress drops and redox-cycling capacity improves, tissues regain their ability to repair, immune signaling becomes more discriminating, and overall pathogen burden tends to diminish because the host environment is no longer permissive to chronic colonization.


Redox Modulation and Biofilm Breakdown

By restoring redox tone, Lussoma re-establishes healthy oxidative gradients and reduces the pool of oxidized host substrates that biofilms depend on as structural scaffolds. This stabilized matrix also supports redox-sensitive antimicrobial enzymes and enhances tissue-level resolution signals that weaken biofilm adhesion, exposing otherwise shielded organisms to immune targeting.

Without sufficient HOI generation to disrupt microbial membranes and quorum signaling, these same biofilms can consolidate, protecting bacteria from immune recognition, antibiotics, and redox-mediated clearance. Lussoma's combined redox normalization and controlled HOI support work together to prevent this progression and maintain a less permissive terrain for biofilm maturation.

HOI Production

The lactoperoxidase system is one of the body's primary front-line antimicrobial defenses, concentrated at mucosal surfaces like the oral cavity, upper airway, lungs, and gastrointestinal tract. At these sites, lactoperoxidase converts iodide into hypoiodous acid (HOI), a fast-acting antimicrobial that keeps bacterial, viral, and fungal loads in check before they gain deeper access.



When functioning properly, this system provides potent microbial control; however, in states of pathogenic burden, where biofilms and persistent colonization challenge the body, HOI production is compromised, and pathogen overload can escalate dramatically.

Restoring LPO Function Through Stabilized Iodide and Redox Control

In chronic illness, one or more of the required inputs is deficient or dysfunctional:

- Iodide (I-) levels may be too low in plasma or poorly distributed to mucosal tissues
- H_2O_2 may be overproduced (damaging) or underproduced (ineffective)
- LPO itself can become oxidatively damaged or underexpressed

What makes Lussoma unique is that its stabilized, buffered iodide matrix remains bioavailable even in hostile, inflamed, or oxidatively stressed environments. Its proprietary composition includes compounds that help:

- Chaperone iodide into epithelial tissues where it's needed
- Maintain redox stability, preventing the iodide from being neutralized prematurely
- Modulate local redox tone, optimizing the H_2O_2 flux required for LPO to function without overwhelming the tissue

Lussoma provides not only the iodide substrate, but also the redox, pH, and substrate-availability environment that LPO needs to produce HOI efficiently. In a disease state, this difference in local biochemistry can determine whether the LPO system remains dormant or becomes fully active.

Additionally, because lactoperoxidase operates deep within glandular and epithelial tissues, Lussoma's stabilized iodide system supports redox balance and maintains iodide in a bioavailable state even in inflamed or low-oxygen environments. This allows iodide to remain at the mucosal interface rather than being neutralized prematurely, keeping it accessible to lactoperoxidase under acidic or inflamed conditions. As a result, the active halogen species generated can penetrate the extracellular polymeric matrix and oxidize key thiol and amino groups on microbial surface proteins and quorum-sensing molecules, destabilizing biofilm structure and disrupting microbial coordination.

Clinical Talking Points

What Lussoma does: Modulates redox tone and reduces pathogenic load.

Why it matters: Supports immune surveillance, mucosal integrity, and clearance of low-grade, persistent infections.

Formulated exclusively from GRAS-designated compounds; each component is recognized as safe under FDA regulations and assembled into a buffered, stabilized complex without introducing any non-GRAS excipients or novel chemical entities.



Safety & Tolerability

Because it modulates iodine pathways, Lussoma should be used with caution in patients taking thyroid medications, ACE inhibitors, or diuretics. Mild coughing can occur in the first few days as the body adapts to signaling at mucosal surfaces.

Dosing Guidance

- Keep 1–2 hours away from high-dose vitamin C or strong reducing agents
- Start with low titration
- Monitor individual response

Side effects to mention: Mild transient cough, metallic taste, brief throat/airway "activation," or detox-like clearing sensations; Herxheimer-like immune responses (e.g., temporary symptom flare or fatigue during microbial clearing). These effects are typically short-lived and indicate active physiologic engagement.

Interaction profile: Safe alongside most antimicrobial, detox, gut, and mitochondrial protocols; no known major interactions.

Contraindication reminders: Avoid during active hyperthyroid states, unmanaged iodine sensitivity, or if advised otherwise by the clinician.

Normal appearance note: Occasionally small soft aggregates may appear in the liquid due to temperature shifts; these are harmless and normal. Simply shake the bottle and they disperse.

Time-course expectations: Benefits tend to accumulate with consistent use. Some patients report early shifts in energy, airway clarity, or immune steadiness, while for others, noticeable effects may emerge gradually over several weeks or even months.

In-office option: Small sample bottle available for supervised first-dose assessment.

Why the website has minimal info: FDA dietary supplement compliance restricts mechanistic or disease-related claims online.

Clinician Access and Overview

Complimentary Evaluation Bottle

Each registered clinician receives one full-size bottle of Lussoma at no cost for personal evaluation and familiarization.

Presentation & Packaging

Each unit arrives in a precision-crafted magnetic presentation box containing one Lussoma bottle and glass dropper.

Ordering & Distribution

Clinicians submit a purchase order request directly through Lussoma's clinician portal (web) or by email, phone, or text message. Bottles are shipped to the clinic, or in special circumstances directly to the patient. Payment is only processed as bottles are sold as part of a low-risk, performance-based model.

Clinical Use Notes

- Delivered in a micro-dosed, titratable format (20 drops typical).
- For clinician-guided protocols only; not an over-the-counter product.
- All dosing, dilution, and delivery decisions must be made solely by the supervising clinician based on individual patient factors.
- No standardized regimen is provided or implied, and use should not be interpreted as treatment for any condition.
- Clinicians should follow their own professional judgment and applicable regulations when incorporating Lussoma into care.

Small-batch availability

Lussoma is produced in limited, tightly controlled batches, so certain lots may have a short 1–2 week wait time when demand exceeds the current run. Each batch also undergoes full Certificate of Analysis (CoA) testing for purity, potency, and safety, and this quality verification step can add additional time before release.

Regulatory Notes

Not for OTC sale. Dispense under clinician guidance.

Certificates of Analysis: Each production lot is accompanied by a full Certificate of Analysis, kept on file and available for clinician review upon request.

Lussoma is offered strictly as a dietary supplement in full alignment with FDA regulations (21 CFR 101.93).

No disease names or treatment claims appear in public materials.

Clinicians are free to discuss observations and therapeutic reasoning privately with patients under standard professional discretion.

Contact

Website: lussoma.com
Email: info@lussoma.com

Tel: 301-452-6171
Calls and messages are returned promptly.

Clinician Portal: lussoma.com/for-clinicians
Password: health

Please direct all correspondence, documentation, and shipments related to Lussoma to the address below:

LUSSOMA
199 E MONTGOMERY AVE
STE 100
ROCKVILLE MD 20850-2361

Payment

Payment may be remitted by check or through the website's clinician portal using standard online payment methods.

Clinical Support & Physician-to-Physician Consultation

If you'd like clinical insight or peer-to-peer discussion, Lussoma can connect you with one of our regional medical directors, each of whom has extensive hands-on experience with the product in a wide range of patient presentations. They're available to discuss clinical considerations, dosing strategies, case nuances, or general questions from a practitioner's perspective. Simply reach out to us by the contact form on our website, email, or phone, and we'll facilitate an introduction to the appropriate director.

Your Feedback Helps Shape Lussoma

Lussoma invites open feedback on every aspect of our work, from product experience and clinical outcomes to packaging, ordering, and support. We encourage practitioners and patients alike to share their observations, questions, or concerns so we can continually refine our processes and maintain the highest standards.



These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided is for educational purposes for licensed healthcare professionals and is not a substitute for individualized clinical judgment.

This document is intended exclusively for licensed clinicians and must not be shared with patients or the general public. It contains mechanistic and regulatory-sensitive information that cannot appear in consumer-facing materials under FDA dietary supplement rules. Distribution outside professional use may expose providers to regulatory, legal, and privacy risk.